Anzeige
Mehr »
Login
Mittwoch, 23.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Goldpreise steigen über $2.700 - Hier ist der Bergbaukonzern, der jetzt davon profitieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
362 Leser
Artikel bewerten:
(2)

Cantourage UK brings Together Pharma's Uganda-grown medical cannabis to the United Kingdom

  • Together Pharma's dried flowers are the first Ugandan medical cannabis products to be made available in the United Kingdom
  • Glueberry OG and Power Plant cultivars will further increase the range of treatment options for medical cannabis patients in the UK at a price lower than the illicit market average
  • Together Pharma's medical products are a strong addition to the offering of Cantourage Clinic, which prescribes medical cannabis to patients throughout the UK

LONDON, June 27, 2022 /PRNewswire/ -- Cantourage UK and Israeli medical cannabis producer Together Pharma (TASE: TGTR) have brought the first Ugandan medical cannabis to the United Kingdom. From today, patients throughout the UK will have access to two of Together Pharma's high-THC genetics: Glueberry OG and Power Plant.

Together Pharma and Cantourage UK

Cantourage UK, a subsidiary of Berlin-based European medical cannabis leader Cantourage, has successfully imported the dried flower products from Germany. Cantourage UK will offer Together Pharma's high-THC, non-irradiated medical cannabis flowers to patients immediately through Cantourage Clinic.

Together Pharma is the only cultivator of medical cannabis in Uganda. Its Ugandan farm extends over some approx. 30,000 sqm Greenhouses and has a full production capacity of more than 15 tonnes annually, including a range of innovative cultivars which will be introduced into the UK's medical cannabis market over the next few months.

As of today, Cantourage has signed contracts with over 20 leading cultivators from 13 different countries. Together Pharma is the first company to launch products grown in Africa via Cantourage's Fast Track Access Platform.

Niall Ivers, COO at Cantourage UK: "We're delighted to be extending our successful partnership with Together Pharma into the UK. Together Pharma is a market leader in the Israeli domestic market with extensive knowledge and international experience in delivering high-quality, great-value medicines to patients. We're confident the introduction of these first two varieties will assist in building a sustainable eco-system for UK patients."

Nir Sosinsky, Managing Director of Together Pharma, added: "Our extended partnership with Cantourage UK is extremely exciting for Together Pharma and a new stage in the expansion of our global reach. It strengthens our position in the UK and Europe, while at the same time underpinning our commitment to Uganda's cannabis industry, which holds great future potential for the country. The United Kingdom is an extremely important market for us. We are glad that our medical-grade cannabis flowers are being made available through Cantourage UK and Cantourage Clinic, allowing for a reliable supply to the benefit of patients across the country."

About Cantourage

Cantourage GmbH is a leading European medical cannabis company. The Berlin-based company was founded in 2019 by industry pioneers Dr Florian Holzapfel, Norman Ruchholtz and Patrick Hoffmann.

With its unique Fast Track Access platform, Cantourage enables producers from across the world to become part of the rapidly growing European medical cannabis market. Cantourage focuses on long-term collaborations and strategic partnerships: each partner along the value chain can focus on what they do best - from growers to logistics, manufacturers to pharmacies and wholesalers. All with one clear goal in mind: to provide patients in Europe with an unprecedented selection of the highest quality cannabis medicines at affordable prices. Cantourage offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol.

Cantourage UK was formed in January 2021 as a joint venture between Cantourage GmbH and NICE Partners, a London-based cannabis company, founded in 2019 by Benjy Cuby, Gabriel Newman, Joshua Cuby and Niall Ivers. The company specialises in developing strategic alliances, business development and compliance in the European cannabis market. Cantourage UK imports medical cannabis products from Germany into the UK and Channel Islands, supplying a broad range of products to patients throughout the country.

About Together Pharma Holdings Inc.

Together Pharma is a public company traded on the Tel Aviv Stock Exchange (TASE). The company has a subsidiary Globus Pharma Ltd., which holds the franchise, (both directly and through subsidiaries), to grow, produce, and distribute medical cannabis products.

The company operates 2 farms of the world's most advanced agricultural cultivation systems, one in Israel and the second in Uganda, which allow the control and supervision of cannabis plants using the latest technologies, developing them into quality plants suitable for supervised medical use according to the strict IMC-GAP and GACP standards. The company has also a pharmaceutical factory, which meet all the required strict conditions for manufacturing medical products according to the IMC-GMP standard.

Photo- https://mma.prnewswire.com/media/1847608/Together_Pharma.jpg
Photo- https://mma.prnewswire.com/media/1847606/CAN_UK_team.jpg
Photo- https://mma.prnewswire.com/media/1847607/Nir_Sosinsky.jpg
Logo- https://mma.prnewswire.com/media/1807078/Cantourage_Logo.jpg

Cantourage UK: Joshua Cuby, Gabriel Newman, Niall Ivers

Together Pharma CEO Nir Sosinsky

(PRNewsfoto/Cantourage)

© 2022 PR Newswire
Sondersituation: Vervielfachungschance bei diesen Goldaktien

Der Goldpreis haussiert und schwingt sich von Hoch zu Hoch. Getrieben von geopolitischen Unsicherheiten sowie der Aussicht auf eine lockere Geldpolitik der FED gehen Experten aktuell von weiter steigenden Notierungen bis sogar in den Bereich von 3.000 US-Dollar je Unze Gold aus.

Im Schatten des Basispreises notieren Goldproduzenten aus der zweiten Reihe sowie Explorationsunternehmen noch weit weg von ihren historischen Höchstständen entfernt und bieten dadurch erhebliches Aufholpotential.

In diesem kostenlosen Report geben wir Ihnen Favoriten an die Hand, die aufgrund von Sondersituation die Chance auf eine Kursvervielfachung besitzen.

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von dem weiter steigenden Kurs des Edelmetalls.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.